The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 47-54

  Hopkins, Sam ^a   Dimassimo, Betty ^a   Rusnak, Pamela ^a   Heuman, Douglas ^b   Lalezari, Jacob ^c   Sluder, Ann ^a   Scorneaux, Bernard ^a   Mosier, Sarah ^a   Kowalczyk, Paul ^a   Ribeill, Yves ^a   Baugh, James ^d   Gallay, Philippe ^d  

^a Scynexis Inc   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Quest Clinical Research   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

2 5 OAS 1; Chronic hepatitis C; Cyclophilin inhibitor; IL28B; Interferon ; Interferon ; SCY 635

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BILIRUBIN; CYCLOPHILIN INHIBITOR; INTERFERON; INTERFERON LAMBDA3; INTERLEUKIN 28B; INTERLEUKIN 29; PLACEBO; SCY 635; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; GENE EXPRESSION; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOKALEMIA; IN VITRO STUDY; INNATE IMMUNITY; JAW PAIN; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLOPHILIN A; CYCLOPHILINS; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84862697734     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.024     Document Type: Article

References (17)

1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
2. Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008;82:5269-5278.
3. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009;284:16998-17005.
4. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009;5:e1000546.
5. Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, et al. SCY- 635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010;54:660-672.
6. Hopkins S, Huang Z, Scribner A, Peel M. Antiviral activity of the non-immunosuppressive cyclophilin inhibitor SCY-635 in combination with investigational and approved anti-HCV agents. Hepatology 2009;50:266A.
7. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, et al. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003;110:201-209.
8. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009;49:1460-1468.
9. Pflugheber J, Fredericksen B, Sumpter Jr R, Wang C, Ware F, Sodora DL, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci USA 2002;99:4650-4655.
10. Fredericksen B, Akkaraju GR, Foy E, Wang C, Pflugheber J, Chen ZJ, et al. Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol 2002;15:29-40.
11. Sumpter Jr R, Loo Y-M, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79:2689-2699.
12. Biron CA. Initial and innate responses to viral infections - pattern setting in immunity or disease. Curr Opin Microbiol 1999;2:374-381.
13. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
14. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
15. Liu J-P, Ye L, Wang X, Li J-L, Ho W-Z. Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis 2011;13:24-32.
16. Hopkins S, Huang Z, Mosier S, Chatterji U, Gallay P. The non-immunosuppressive cyclophilin inhibitor SCY-635 inhibits the association of NS5A and cyclophilin A. Hepatology 2010;52:338A.
17. Brazin KN, Mallis RJ, Fulton DB, Andreotti AH. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA 2002;99:1899-1904.